Valuing the Unvalued: Scientific Promise Is Not Financial Value
Why understanding value creation matters for life sciences founders and CEOs.
I have worked with many life sciences founders who believe their companies are worth considerably more than investors are willing to pay.
The science is compelling. The intellectual property is strong. The clinical opportunity is meaningful.
Surely that creates value.
It does. But the value you create is not necessarily the value someone is willing to pay for it.
That distinction is central to Chapter 3 of the book, Dual Fluency.
Why Does Valuation Matter?
Life sciences companies frequently ask investors to value something that does not yet exist commercially.
A drug may be years from approval. A diagnostic may lack reimbursement. A medical device may have promising clinical data but no established market.
Founders see scientific potential. Investors see probabilities, development costs, timelines, competition, and financial risk.
Neither perspective is wrong. But failing to understand the difference can be costly.
Scientific progress does not automatically translate into financial value.
Valuation Is More Than a Number
Valuation is not something that happens only during a financing or acquisition.
Every decision to advance a program, initiate a clinical trial, pursue a partnership, or abandon an asset is fundamentally a valuation decision.
The question is not simply whether the science is good.
It is whether the next dollar invested creates sufficient risk-adjusted value to justify the commitment.
And sometimes the most valuable decision a CEO can make is to stop funding a program they passionately believe in.
That requires discipline, not just conviction.
The Leadership Imperative
Founders and CEOs must understand three things:
-
- What actually drives the value of their scientific assets.
-
- How investors and strategic partners price risk and uncertainty.
-
- When continued investment creates value and when it destroys it.
Great science creates opportunity. Great capital allocation determines how much of that opportunity becomes value.
That is why understanding valuation matters.
And why Valuing the Unvalued is central to Dual Fluency.
This article introduces Chapter 3, “Valuing the Unvalued,” from my book, Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital.
What do you think? Are life sciences founders too focused on what their science is worth rather than what investors are actually willing to pay?
David H. Crean, PhD
Author, Dual Fluency